Do you want to read an article? Please log in or register.
Mini Review: Erlotinib as first-line treatment for NSCLC – an overview of the data currently available
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Related content
COMMENTED
Genitourinary Cancer
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Navani V, Heng DYC
doi: 10.1001/jamaoncol.2021.4337
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Lung, Respiratory and Thoracic Cancer
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
Expert Rev Anticancer Ther.
Brückl W, Tufman A, Huber RM
doi: 10.1080/
Lung, Respiratory and Thoracic Cancer
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
J Clin Oncol.
Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA
doi: 10.1200/JCO.2017.74.7576.
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
N Engl J Med.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group
doi: 10.1056/NEJMoa1716948.
Genitourinary Cancer
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials
Semin Oncol
Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Pradere B, Motlagh RS, Enikeev D, Shariat SF, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
doi: 10.1053/j.seminoncol.2021.09.005
Lung, Respiratory and Thoracic Cancer
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Lancet Oncol.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS
doi: 10.1016/
Genitourinary Cancer
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Eur Urol.
Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, Heng DYC, Satkunasivam R, Finelli A
doi: 10.1016/j.eururo.2018.03.036.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Lung Cancer.
Dafni U, Tsourti Z, Vervita K, Peters S
doi: 10.1016/j.lungcan.